{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04353830",
      "orgStudyIdInfo": {
        "id": "CIBI939A101"
      },
      "organization": {
        "fullName": "Innovent Biologics (Suzhou) Co. Ltd.",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors",
      "officialTitle": "A Phase 1a, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors"
    },
    "statusModule": {
      "statusVerifiedDate": "2023-02",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2020-05-22",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2022-05-11",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2022-05-11",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2020-04-17",
      "studyFirstSubmitQcDate": "2020-04-17",
      "studyFirstPostDateStruct": {
        "date": "2020-04-20",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2023-02-28",
      "lastUpdatePostDateStruct": {
        "date": "2023-03-01",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Innovent Biologics (Suzhou) Co. Ltd.",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI939 in subjects with advanced malignancies"
    },
    "conditionsModule": {
      "conditions": [
        "Advanced Malignancies"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 34,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Phase Ia Dose-Escalation Stage:IBI939",
          "type": "EXPERIMENTAL",
          "description": "Participants will be treated with escalating doses of IBI939 to determine the MTD.",
          "interventionNames": [
            "Drug: IBI939"
          ]
        },
        {
          "label": "Phase Ia Dose-Escalation Stage:IBI939+ Sintilimab",
          "type": "EXPERIMENTAL",
          "description": "Participants will be treated with escalating doses of IBI939 in combination with a fixed dose of Sintilimab to determine the MTD.",
          "interventionNames": [
            "Drug: IBI939+ Sintilimab"
          ]
        },
        {
          "label": "Phase Ib Expansion Stage:IBI939+ Sintilimab",
          "type": "EXPERIMENTAL",
          "description": "Participants will be enrolled in the expansion stage to better characterize the safety, tolerability, PK variability, and preliminary efficacy of IBI939 in combination with Sintilimab in different cancer types.",
          "interventionNames": [
            "Drug: IBI939+ Sintilimab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "IBI939",
          "description": "Several dose levels will be evaluated for IBI939 administered as a single agent and in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI939 may receive combination treatment with Sintilimab or IBI939+ Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.",
          "armGroupLabels": [
            "Phase Ia Dose-Escalation Stage:IBI939"
          ]
        },
        {
          "type": "DRUG",
          "name": "IBI939+ Sintilimab",
          "description": "IBI939: Several dose levels will be evaluated for IBI939 in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.\n\nSintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit.",
          "armGroupLabels": [
            "Phase Ia Dose-Escalation Stage:IBI939+ Sintilimab"
          ]
        },
        {
          "type": "DRUG",
          "name": "IBI939+ Sintilimab",
          "description": "IBI939: IBI939 in combination with Sintilimab will be given with RP2D. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.\n\nSintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit.",
          "armGroupLabels": [
            "Phase Ib Expansion Stage:IBI939+ Sintilimab"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Number of subjects with AEs and SAEs",
          "description": "To evaluate the safety and tolerability of IBI939 alone or in combination with Sintilimab \\[Adverse events (AEs), Serious Adverse Events (SAEs) \\]",
          "timeFrame": "up to 2 years after enrollment"
        },
        {
          "measure": "Percentage of Participants with Dose-Limiting Toxicities (DLTs)",
          "description": "To evaluate the safety and tolerability of IBI939 alone or in combination with Sintilimab.",
          "timeFrame": "From Baseline to the end of Cycle 1"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Pharmacokinetics: AUC",
          "description": "The area under the curve (AUC) of serum concentration of the drug after the administration.",
          "timeFrame": "up to 2 years after enrollment"
        },
        {
          "measure": "Pharmacokinetics: Cmax",
          "description": "Maximum concentration (Cmax) of the drug after administration",
          "timeFrame": "up to 2 years after enrollment"
        },
        {
          "measure": "Immunogenicity: Percentage of ADA positive subjects",
          "description": "Immunogenicity: Number of Anti-Drug Antibodies (ADA) positive subjects will be counted and percentage of ADA positive subjects will be calculated to evaluate immunogenicity of IBI939.",
          "timeFrame": "up to 2 years after enrollment"
        },
        {
          "measure": "Preliminary anti-tumor activity (Objective Response Rate)",
          "description": "Objective Response Rate (ORR) is the percentage of Complete Response (CR) plus partial response (PR) assessed by RECIST v1.1 criteria for solid tumors.",
          "timeFrame": "up to 2 years after enrollment"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Able to understand and willing to sign the ICF.\n2. Adults 18 years of age or older.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. Life expectancy at least 12 weeks.\n5. Adequate organ and bone marrow function.\n\nEligibility Criteriaï¼š\n\n1. Previous exposure to any anti-TIGIT antibody.\n2. Participate in another interventional clinical study, except for the observational (non-interventional) clinical study or the survival follow-up phase of the interventional study.\n3. Any investigational drugs received within 4 weeks prior to the first study treatment.\n4. Receive the last dose of anti-tumor therapy within 4 weeks before the first dose of study therapy.\n5. Immunosuppressive drugs were used within 4 weeks prior to the first administration of the study drug.\n6. Medication requiring long-term systemic hormones or any other immunosuppression therapy.\n7. Major surgical procedures (craniotomy, thoracotomy, or laparotomy) or unhealed wounds, ulcers, or fractures were performed within 4 weeks prior to the first dose of study therapy.\n8. Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases, or leptomeningeal disease.\n9. History of autoimmune disease , present active autoimmune disease or inflammatory diseases\n10. Positive human immunodeficiency virus (HIV) test.\n11. Active hepatitis B or C, or tuberculosis.\n12. History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n13. Known history of hypersensitivity to any components of the IBI939 or Sintilimab.\n14. Pregnant or nursing females.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "75 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Peking University Cancer Hospital & Institute",
          "city": "Beijing",
          "country": "China",
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-18"
    }
  },
  "hasResults": false
}